Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

What Causes Knee, Hip & Hand Osteoarthritis

Arthritis & Rheumatology  |  September 25, 2019

Introduction & Objectives

Osteoarthritis (OA) is the most common form of arthritis in developed countries, representing an increasing health economic burden.1 Patients with knee or hip OA have excess all-cause mortality compared with the general population, and there is no curative treatment for OA.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Besides age and sex, modifiable factors have been shown to be associated with the risk for OA, the highest level of evidence being for obesity and joint injury.3,4 Obesity is a major risk factor for OA incidence and progression at the knee, and to a lesser extent, at the hip.5 In addition, the role of obesity is strongly supported by findings of improvement of knee symptoms in patients undergoing weight loss.6,7 Body mass index (BMI) and other factors are associated with prevalence, incidence or progression of OA. High bone mineral density (BMD) is associated with an increased risk of radiographic hip OA or knee OA and with total joint replacement.8-10 Results from prospective studies of incident radiographic OA or OA progression are controversial.11

The concept of a “metabolic OA” phenotype was recently proposed.4 However, because metabolic factors are closely related to BMI, their BMI-independent contribution to the risk of OA is unknown. Previous studies have shown that the presence of the metabolic syndrome and many of its components are associated with the risk of hand and knee OA.12-14 Most associations with each of the metabolic syndrome components, however, become nonsignificant after adjustment for BMI.13,15

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In addition, conflicting data regarding type 2 diabetes as a BMI-independent predictor of OA have been reported.16,17 The results from classic epidemiologic studies may be affected by residual confounding or reverse causation.

Funck-Brentano et al. hypothesized that causal associations may differ by OA site, and they undertook this study to identify causal risk factors of knee, hip and hand OA.

Methods

Individual-level data from 384,838 unrelated participants in the UK Biobank study were analyzed. Mendelian randomization analyses were performed to test for causality for BMI, BMD, serum high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride levels, type 2 diabetes, systolic blood pressure (BP) and C-reactive protein (CRP) levels. The primary outcome measure was OA determined using hospital diagnoses (all sites, n=48,431; knee, n=19,727; hip, n=11,875; hand, n=2,330). Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated.

Results

Mendelian randomization analyses demonstrated a robust causal association of genetically determined BMI with all OA (OR per SD increase 1.57 [95% CI 1.44–1.71]), and with knee OA and hip OA, but not with hand OA. Increased genetically determined femoral neck BMD was causally associated with all OA (OR per SD increase 1.14 [95% CI 1.06–1.22]), knee OA, and hip OA. Low systolic BP was causally associated with all OA (OR per SD decrease 1.55 [95% CI 1.29– 1.87]), knee OA, and hip OA. There was no evidence of causality for the other tested metabolic factors or CRP level.

Conclusion

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & Rheumatologyhand osteoarthritishipkneeKnee Osteoarthritis (OA)osteoarthritis (OA)Research

Related Articles

    Mechanistic, Epidemiologic Clues Suggest Possible Link Between Obesity, Inflammation in Rheumatoid Arthritis

    October 11, 2016

    Obesity has an established systemic inflammatory component. Could that be a trigger for the inflammation seen in rheumatoid arthritis (RA) and other rheumatic diseases? Although there is no direct scientific evidence, both mechanistic and epidemiologic clues do give some intriguing suggestions of a possible link. “At first, we thought that fat was involved only in…

    Gout, Glucose Metabolism and Obesity: A Case Review

    November 2, 2014

    New research explores association between hyperurecimia and gout with metabolic derangement

    Elevated BMI Associated with Pain in Patients with Hand OA

    November 8, 2022

    Research from Gloersen et al. suggests the systemic effects of obesity, as measured by leptin, may play a role in the severity of pain experienced by patients with hand osteoarthritis.

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences